Cerecor (CERC) Surges with Alkermes (ALKS) Following Positive Depression Trial Results

October 20, 2016 5:43 PM EDT
Get Alerts CERC Hot Sheet
Trade CERC Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Cerecor (NASDAQ: CERC) is surging 62.9% after competitor Alkermes plc (NASDAQ: ALKS) announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. Shares of Alkermes are up 37.9% on the news.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment